Overview of COVID-19 Lung Damage Clinical Trial

Posted in Clinical Trials & Pilot Studies, Ideas & Innovations | 1 minute read

June 16th, 2020

SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial to treat post-COVID 19 survivors with AD cSVF.

Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.

This article was published in Stem Cell Research.

Want to learn more from Dr. Alexander?

Visit the SDARTs Online Learning Center >